Pfizer-BioNTech Halts COVID-19 Vaccine Trial in Healthy Adults Aged 50-64
• Pfizer and BioNTech stopped a large US trial of their updated COVID-19 vaccine targeting healthy adults aged 50-64 due to inability to recruit 25,000-30,000 participants without conditions like hypertension or diabetes. • The halt highlights recruitment challenges amid low interest in trials for healthy populations. • This occurs against a backdrop of shifting vaccine policies under the Trump administration, prioritizing chronic disease over broad COVID efforts.
cidrap.umn.edu